• 2022 IMSA SportsCar Championship to kick off with 24 Hour endurance at Daytona
• Motul supporting GTD Pro teams Pfaff Motorsports and BMW M Team RLL
• IMSA and Motul continue partnership for 2022 season

Singapore, Jan 28, 2022 - (ACN Newswire) - The 2022 IMSA WeatherTech SportsCar Championship is set to get underway with one of the most historic races of the calendar. The 2022 Rolex 24 at Daytona will mark the 60th running of the 24-hour endurance classic at Daytona International Speedway to be held on 29th and 30th January. Motul will be powering the efforts of 2 teams, Pfaff Motorsports and BMW M Team RLL with their range of high-performance racing-grade lubricants, in the newly introduced GT Daytona Pro (GTD Pro) category.

The 2022 IMSA WeatherTech SportsCar Championship is set to get underway with one of the most historic races of the calendar. The 2022 Rolex 24 at Daytona will mark the 60th running of the 24-hour endurance classic at Daytona International Speedway to be held on 29th and 30th January. Motul will be powering the efforts of 2 teams, Pfaff Motorsports and BMW M Team RLL with their range of high-performance racing-grade lubricants, in the newly introduced GT Daytona Pro (GTD Pro) category.

Pfaff Motorsports secured the GTD Championship in 2021 after a dominant performance. Motul's collaboration with the team began in 2020 and has been a fruitful one on and off the track. The #9 Motul Porsche 911 GT3 R concluded the previous season with 6 podiums and 4 unmatched class victories. They will be returning with the familiar "Plaid Porsche" livery and a brand new driver line-up featuring Porsche works drivers Matt Campbell (AUS) and Mathieu Jaminet (FRA) for the full season, along with 2-time IMSA DPi champion Felipe Nasr (BRA) for the seasons' four endurance rounds. Pfaff Motorsports continues to place its trust in Motul lubricants for the 2022 season too.

Motul is also a long time partner of BMW M Team RLL, which will also be making its GTD Pro class debut at this event with the new and highly anticipated BMW M4 GT3. In 2021, BMW bid farewell to the M8 GTE at Petit Le Mans, which was racing in the now-defunct GT Le Mans class. Starting this season, the BMW team will be competing in the GTD Pro class with their refreshed 2-car line-up, the #24 Motul BMW M4 GT3 and #25 Motul BMW M4 GT3. The #24 will be driven by Philipp Eng (AUT), Marco Wittmann (DEU), Nick Yelloly (GBR) and Sheldon van der Linde (ZAF) whilst the #25 car will be piloted by Connor De Phillippi (USA), John Edwards (USA), Augusto Farfus (BRA) and Jesse Krohn (FIN). 6 of the 8 drivers racing at Daytona also contested in the M8 GTE last year, with the other 2 having plenty of previous experience in the series. Both teams look strong going into the season opener, which is gearing up to be an exciting race weekend.

Motul became the "Official Motor Oil" of the IMSA SportsCar Championship in 2018 to support the top teams on the grid with the highest quality of synthetic lubricants. Their proprietary 300V along with RBF 700 brake fluid and other critical lubricants are vital in a championship series that features a mix of long and short races. Motul is a major part of the series, being title sponsor for Motul Petit Le Mans along with established partnerships across seven venues and events on the calendar. The Rolex 24 at Daytona is guaranteed to showcase thrilling multi-class racing action as the teams gear up to tackle the constantly changing conditions. The round the clock race also presents Motul with the opportunity to understand how their products perform in different machinery and constantly improve formulation to bring similar performance to everyday customers.

60th Rolex 24 at Daytona Schedule (all times in GMT -5)

Race Start - 29 January | 1:40 PM | Saturday
Race End - 30 January | 1:40 PM | Sunday

About MOTUL

Motul is a world-class French company specialised in the formulation, production and distribution of high-tech engine lubricants (two-wheelers, cars and other vehicles) as well as lubricants for industry via its Motul Tech activity. Motul offers a whole range of products for everyday car use, including the 8100, H-tech, RBF series, ATF, CVTF and DCTF among others. Motul products ensure all parts of the car are kept in pristine condition to extract maximum performance and reliability.

Unanimously recognised for more than 150 years for the quality of its products, innovation capacity and involvement in the field of competition, Motul is also recognised as a specialist in synthetic lubricants. As early as 1971, Motul was the first lubricant manufacturer to pioneer the formulation of a 100% synthetic lubricant, issued from the aeronautical industry, making use of esters technology: 300V lubricant. In 2021, Motul launched the newest iteration of the 300V with revolutionary technology, setting a new benchmark for high-performance lubricants.

Motul is a partner to many manufacturers and racing teams in order to further their technological development in motorsports. It has invested in many international competitions as an official supplier for several championship winning racing teams.

Motul is committed to its growing business presence in Asia Pacific. Over the years, the company has expanded operations significantly. Currently it has 3 major manufacturing facilities and 2 R&D centres across the region to cater to the ever-growing demand. These centres focus on refining the lubricant technology for Asian climate and driving conditions, which are vastly different from Europe.

MOTUL Asia Pacific Pte. Ltd
1A International Business Park, #06-03
Singapore 609933
www.motul.com

For more information, please contact Motul at [email protected]

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comThe 2022 IMSA WeatherTech SportsCar Championship is set to get underway with one of the most historic races of the calendar.

The largest crypto exchange by trading volume, Binance, is under fire from its users in Nigeria over the “unreasonable” closure of their accounts amidst other inappropriate activities carried out by the platform.

The post Nigerians attack Binance, trends #BinanceStopScamming appeared first on CryptoSlate.

$8 Billion Flushing Bank to Offer Bitcoin Services | Fidelity Files to Launch ETF Tied to Metaverse | Draft Bill Could Let U.S. Treasury Block International Crypto Transactions

TOKYO, Jan 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022. CEO Naito represented pharmaceutical companies and highlighted the achievements of NTDs elimination activities by the industry and successes achieved by multi-sectoral partnerships. He also expressed Eisai's continued support for the elimination of NTDs towards the achievement of NTD road map 2021-2030 launched by the World Health Organization (WHO) last year. The 10th anniversary event aimed to recognize a decade of progress since the London Declaration, to confirm the strong commitment of stakeholders to continue the efforts for NTDs, and to strengthen endorsements from stakeholders to the Kigali Declaration on NTDs, the successor of the London Declaration which will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda.

Tremendous achievements have been made through public-private partnership since the launch of the London Declaration to 2020. The pharma industry has contributed to the elimination of NTDs via supply of medicines which resulted in donation of 13 billion high-quality treatments. Forty-three countries have eliminated at least one NTD and 600 million people no longer require interventions against NTDs. Despite such progress, more than 1.7 billion people remain threatened by NTDs.

In the event, CEO Haruo Naito said, "Our initiatives toward NTDs elimination are rooted in the pharmaceutical company's fundamental mission to deliver medicines to those who need them to treat illness and save lives. While R&D for NTDs treatments have become more active after the London Declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. Utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure."

Under the London Declaration, Eisai has been manufacturing and supplying diethylcarbamazine (DEC) tablets, one of the lymphatic filariasis (LF) treatments, free of charge to the WHO for the elimination of LF. To date, 2.05 billion DEC tablets manufactured at Eisai's Vizag Plant in India have been supplied to 29 countries (as of January 2022). Although LF has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. Eisai is committed to providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries. In addition to the supply of DEC tablets, Eisai is working on various initiatives such as support for the mass drug administrations (MDA), disease awareness and improvements in sanitation.

Furthermore, Eisai is proactively engaged in development of new treatments for NTDs through partnerships with global research organizations. Utilizing the funding from the Global Health Innovative Technology Fund (GHIT Fund) and others, Eisai is conducting joint development of new treatments such as a new treatment for LF in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the Drugs for Neglected Diseases initiative (DNDi).

Eisai commits to the Kigali Declaration and strengthens collaborations with global partners to tackle NTDs towards the achievement of NTD road map 2021-2030.

Based on human health care (hhc) philosophy, Eisai seeks to contribute to the health and welfare of people in developing and emerging countries. Once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. Eisai considers this to be a long-term investment in creating the markets for the future. Eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including NTDs and facilitate initiatives to improve access to medicine such as support for MDAs and disease awareness activities. Through these initiatives, Eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

About Neglected Tropic Diseases (NTDs)

Neglected Tropic Diseases (NTDs) include 20 diseases that the WHO identifies as tropical diseases which human race must overcome. More than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of NTDs infection. The spread of NTDs is mainly caused by poor hygienic conditions associated with poverty. Infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. In the worst cases, NTDs may also result in death. The prevalence of NTDs is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.
The following 20 NTDs have been designated by WHO for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (Hansen's disease], Chagas disease, human African trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

About London Declaration on Neglected Tropical Diseases

On January 30, 2012, the CEOs of 13 pharmaceutical companies*, the Bill & Melinda Gates Foundation, WHO, the U.S. Agency for International Development (USAID), the U.K. Department for International Development (DFID), the World Bank, and officials from NTD-endemic countries gathered in London to pledge their support for a coordinated effort to combat 10 NTDs**. The London Declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat NTDs.

Commemorating the London Declaration, January 30 has been designated as the World NTD Day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of NTDs. Eisai is sponsoring the light up of Tokyo Tower to raise disease awareness and disseminate the importance of eliminating NTDs.

* Abbvie, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, GlaxonSmithKline, Gilead, Johnson & Johnson, Merck (Merck KGaA: Germany), Merck Sharp & Dhome, Novartis, Pfizer, Sanofi
** Guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human African trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, Chagas disease, and visceral leishmaniasis

About Kigali Declaration on Neglected Tropical Diseases

As the successor of the London Declaration on NTDs launched in 2012, the Kigali Declaration represents a collective commitment from stakeholders to fight against NTDs. With the endorsements from stakeholders being initiated at the online event entitled "100% COMMITTED to End NTDs", a campaign to commemorate the 10th year anniversary of the London Declaration held on January 27, 2022, the Kigali Declaration will be unveiled at the Commonwealth Heads of Government Meeting (CHOGM) scheduled for June 2022 in Kigali, the capital of the Republic of Rwanda. To achieve the WHO's NTD roadmap 2021-2030, the Kigali Declaration aims to tackle NTDs comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for NTDs and ensuring equitable access to these NTDs related products and services.

About Lymphatic Filariasis

Lymphatic filariasis (LF) is an NTD transmitted to humans via carrier mosquitoes. LF causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. As a result, patients suffer mental, social and financial losses. It is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of LF. Elimination of LF is possible by stopping the spread of the infection through MDAs of three types of LF treatments including DEC tablets.

About Eisai's Commitment to Improving Global Access to Medicines including LF Elimination Program

In line with its hhc philosophy, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

In November 2010, Eisai agreed to supply a total of 2.2 billion DEC tablets to the WHO free of charge by 2020, as there was a global shortage of high-quality DEC tablets for use in MDAs. In 2012, Eisai became the only Japanese company to participate in the London Declaration, a coordinated effort to eliminate 10 NTDs and the largest public-private partnership of its kind in the field of global health. At the London Declaration's fifth anniversary event held in April 2017, Eisai announced its plan to supply DEC tablets continuously beyond 2020, until LF is eliminated in all endemic countries where DEC tablets are needed.

Eisai has supplied 2.05 billion tablets to 29 countries through the WHO's elimination program (as of January 2022). Furthermore, in order to support the smooth implementation of the WHO's MDA programs, Eisai is engaging in initiatives to raise public awareness of LF in endemic countries. Staff members of Eisai Group cooperate with the relevant representatives in endemic countries to eliminate LF as early as possible.

In addition to the above-mentioned initiatives, Eisai is moving ahead with new drug development projects targeting malaria and NTDs such as mycetoma and LF, based on partnerships with international non-profit organizations such as the Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV), as well as research organizations such as Liverpool School of Tropical Medicine, University of Kentucky, and the Broad Institute (please refer to the table above).

Furthermore, Eisai co-established the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public-private partnership to advance development of new health technologies for the developing world, is a member of the World Intellectual Property Organization (WIPO) Re:Search Consortium, an international joint enterprise for the development of treatments for NTDs, malaria and tuberculosis led by WIPO, is a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, and is participating in the Access Accelerated initiative to promote prevention and treatment of non-communicable diseases.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that its CEO Haruo Naito participated in the online event entitled "100% COMMITTED to End NTDs" celebrating the 10th anniversary of the London Declaration, an international public-private partnership to eliminate neglected tropical diseases (NTDs), on January 27, 2022.

HONG KONG, Jan 28, 2022 - (ACN Newswire) - EuroEyes International Eye Clinic Limited ("EuroEyes" or the "Company", together with its subsidiaries, the "Group", stock code: 1846), a leading global vision correction service provider, is pleased to announce that EuroEyes UK, a wholly-owned subsidiary of the Company, has entered into a Share Purchase Agreement ("Share Purchase Agreement") to acquire the entire issued shares in London Vision Clinic Partners Limited ("LoVC") with the legal and beneficial owners of LoVC ("Sellers").

According to the share purchase agreement, the total cash consideration and consideration shares for the acquisition shall be GBP13,130,000; the maximum amount of earn out payment shall be GBP17,745,000, and subject to the Consideration Adjustment. The maximum consideration for the Acquisition shall be GBP 30,875,000. In terms of earn out payment, under the first profit target, if the Seller maintains an EBIT growth of 12.5% for four consecutive years, EuroEyes shall procure the allotment and issue to the Seller such number of shares having an aggregate value of up to GBP3,120,000; Under the second profit target, if the Seller achieves an EBIT growth rate of 35% for three consecutive years, and 25% in the fourth year, Euroeyes shall pay GBP 9,750,000 to the Seller.

Upon Completion, the Seller (or the Partners as nominated in accordance with the terms and conditions of the Share Purchase Agreement) will hold approximately 1.20% of the issued share capital of EuroEyes as enlarged by the allotment and issue of the Completion Consideration Shares. The Completion Consideration Shares will be issued at the issue price of HK$8.323 per Completion Consideration Share which represents a discount of approximately 6.9% to the average closing price of HK$8.94 per Share as quoted on the Stock Exchange on the five consecutive trading days ended on the trading day immediately preceding 20 January 2022. The shareholding will serve as an share incentive to motivate and retain London Vision Clinic's partners and key surgeons.

London Vision Clinic Partners Limited is one of the leading brands in the vision correction industry and principally engaged in the provision of premium vision correction services, including PRK, LASIK, SMILE, phakic lens (ICL) surgery and refractive cataract surgery. It has been the market segment and price leader in the UK with its capabilities in conducting detailed and comprehensive testing and diagnosis and has a world reputation for expertise in providing training to specialist surgeons and managing complicated cases.

Moreover, LoVC is a world leader in offering laser vision correction option for reading vision in ageing eyes (presbyopia). Its founder, Professor Dan Zoltan Reinstein, has garnered worldwide reputation for his inventions and major contributions to the refractive surgery field, including the invention of the PRESBYOND Laser Blended Vision treatment as commercialised by Carl Zeiss Meditec for presbyopia which is designed to treat patients from the age of 40 years old, who have developed presbyopia (decreased ability to read up close). PRESBYOND provides an additional method of treating younger patients with presbyopia by a LASIK procedure, which avoids the need to perform surgery inside the eye to replace the natural lens. Presbonyd will a perfect addition to EuroEyes' trifocal lens exchange surgery, which enables EuroEyes to treat a larger group of presbyopia patients over 40 years old without buying new equitments.

In addition, London Vision Clinic has a talent pool of high-quality surgeons and doctors. Upon completion of the Acquisition, EuroEyes will continue to hire the expert group to further strengthen its medical expertise. What's more, Professor Reinstein will serve as a medical director of the international medical advisory board of the Group, which will add tremendous value to EuroEye's expert team.

Professor Reinstein is also a bioengineering pioneer, inventor and developer in the field of layered corneal mapping and imaging and biometry. He had pioneered corneal imaging and biometry with very high-frequency digital ultrasound scanning, invented the Arcscan Insight 100 robotic scanner as well as optical coherence tomography (OCT) devices, enabling superior diagnostic capabilities to improve the safety and accuracy of both laser corneal and ICL surgery. Application of his patented biometric technologies has resulted in major contributions to the clinical and scientific development of both LASIK and SMILE.

Moreover, London Vision Clinic Training, a wholly-owned subsidiary of LoVC, will start business afer acquisition, and will be principally engaged in the provision of online and offline training relating to refractive surgery. Professor Reinstein will be one of the key speakers and trainers at London Vision Clinic Training.

In addition, in terms of the financial position of the target company, London Vision Clinic Partners Limited has shown strong growth potential, with a substantial increase in EBIT from GBP 94,000 in 2020 to GBP 2.19 million in 2021. This growth is mainly due to the proactive optimizations and improvements in its business model and operation management made by LoVC started in early 2021.

Dr. Jorn Slot Jorgensen, Founder, Chairman and CEO of EuroEyes said, "The Group has been actively expanding its current footprint in Europe and the acquisition of LoVC is definitely in line with our growth strategy. We believe that the acquisition will enable the Group to quickly tap into the high-end London market for refractive and presbyopic surgeries, create synergy and support the long-term growth of the Group, thereby enhancing its market leader status. With the additions of LoVC and its PRESBYOND Laser Blended Vision treatment, the Group will be able to reach out to more potential patients who are suffering from presbyopia at an early stage. Following the acquisition of LoVC, we plan to open a new clinic in London within 1-2 year, to further expand our service network and provide more patients with high-quality eye care services."

About EuroEyes International Eye Clinic Limited
EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark and the PRC. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation).

Issued by Porda Havas International Finance Communications Group for and on behalf of EuroEyes International Eye Clinic Limited. For further information, please contact:

Porda Havas International Finance Communications Group
Email: [email protected]


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEuroEyes International Eye Clinic Limited ("EuroEyes" or the "Company", together with its subsidiaries, the "Group", stock code: 1846), a leading global vision correction service provider, is pleased to announce that EuroEyes UK, a wholly-owned subsidiary of the Company

Coinbase is proud to be one of the most trusted platforms in crypto, and we recognize that the best way to build trust...

MedX Health with ProMed Pharmacy and Dura Wellness Clinic launches Dermsecure® Screening MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–Teledermatology company MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and […]

The post MedX Health Announces Addition of Two New Screening Services Locations in Ottawa appeared first on Fintech News.

Latest member of the Texas Bankers Association to partner with IronNet in Collective Defense MCLEAN, Va.–(BUSINESS WIRE)–$IRNT–IronNet, Inc. (NYSE: IRNT) (“IronNet”), an innovative leader transforming cybersecurity through Collective Defense, today announced that a Texas-based bank — which is remaining anonymous for operational security reasons — has chosen IronNet’s Collective Defense platform to help it defend […]

The post Major Texas-based Bank Bolsters Cybersecurity Posture with Addition of IronNet Collective Defense Platform appeared first on Fintech News.

With Wildfire Information Still a Priority, New Hazard Awareness & Warning Center Enables Faster, Better Response to Storms, Earthquakes and More OAKLAND, Calif.–(BUSINESS WIRE)–Opened in 2018, Pacific Gas and Electric Company’s (PG&E) Wildfire Safety Operations Center (WSOC) has successfully served as the company’s 24/7 hub for monitoring wildfire risks and for wildfire coordination, prevention and […]

The post PG&E Expands Scope of Wildfire Safety Center to Encompass, Ensure Readiness for Any Natural Disaster and Emergency appeared first on Fintech News.

We know the idea of Gresham's law — but it cannot be applied directly to bitcoin without some modification.

Oil WTI crude prices reversed earlier gains as the dollar surged following better-than-expected economic data that supported the idea that the economy can handle rapid Fed rate hikes. No one is questioning how tight the oil market remains, but there is some exhaustion after making fresh seven-year highs and that has led to some profit-taking. […]

Wide-bore authorization to limit or freeze transactions in a new draft bill has the crypto industry calling foul.

The post Crypto advocates sound alarm on America COMPETES bill over new financial surveillance provisions appeared first on The Block.